Bionano Genomics reported a 13% revenue decrease in Q2 2025 to $6.7 million, reflecting business restructuring focused on optical genome mapping and Via software routine users. Product sales slightly declined, while service revenues dropped significantly following discontinuation of clinical services. The company expanded its installed base of genome mapping systems and flow cell sales but posted a $6.9 million net loss, an improvement from previous year. Bionano reaffirmed full-year revenue guidance and increased expected new instrument installations.